エピジェネティクス医薬品と診断技術の市場調査レポート：2032年までの予測

Epigenetics Drugs and Diagnostic Technologies Market Research Report Forecast to 2032

エピジェネティクス医薬品と診断技術の市場調査レポート：2032年までの予測市場概要エピジェネティクス医薬品および診断技術市場は、調査期間中に21.90%の大幅なCAGRを記録すると予測されています。市場... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Market Research Future マーケットリサーチフューチャー (MRFR)	2023年10月12日	US$7,250 ライセンス・価格情報・注文方法はこちら	128	英語

目次
図表リスト

サマリー

エピジェネティクス医薬品と診断技術の市場調査レポート：2032年までの予測

市場概要
エピジェネティクス医薬品および診断技術市場は、調査期間中に21.90%の大幅なCAGRを記録すると予測されています。
市場の発展は、局所感覚系（CNS）疾患や腫瘍学のような持続性疾患の蔓延の高まりや、製品派遣やパイプライン製品の増加のような要素によって牽引されています。
世界中で進行中の局所感覚系疾患の罹患率が上昇しており、エピジェネティック医薬品や診断技術の需要が拡大しています。エピジェネティクスは、アルツハイマー病、ハンチントン病、統合失調症、化学的不均衡、双極性障害などの局所感覚系疾患を大幅に治療します。さらに、これらの薬剤は毒性が低く、より良い治療のために異なる種類の薬剤と混合して投与することができる。
さらに、エピジェネティクスは悪性腫瘍の治療において驚異的な成果を示しており、これらの薬剤はデオキシリボ核酸（DNA）のスイッチを切ることができる。GLOBOCAN 2020によると、胸部疾患が最大の市場規模を占めており、次いで肺、大腸、前立腺、胃、その他の悪性腫瘍となっている。
市場セグメント
エピジェネティクス医薬品と診断技術の市場は、薬剤のタイプに基づき、DNAメチル基転移酵素（DNMT）阻害剤、ヒストン脱アセチル化酵素（HDAC）阻害剤、ヒストンメチルトランスフェラーゼ（HMT）阻害剤、およびブロモドメイン阻害剤、タンパク質メチルトランスフェラーゼ阻害剤、ヒストンアセチルトランスフェラーゼ（HAT）阻害剤を含むその他に区分される。DNAメチル基転移酵素（DNMTs）阻害剤セグメントは、アザシチジン、デシタビン、その他（ゼブラリン、ヒドララジン、プロカインなど）にさらに分類され、ヒストン脱アセチル化酵素（HDACs）阻害剤は、ボリノスタット、ロミデプシン、その他（ベリノスタット、パノビノスタット、トリコスタチンAなど）にさらに分類される。
診断技術セグメントは、DNAメチル化およびヒストン修飾解析と、ノンコーディングRNA解析およびエピゲノムプロファイリングを含むその他に分類される。
用途別では、がん、神経、自己免疫疾患、その他に分類される。エンドユーザーに基づくと、市場は病院・診療所、診断センター、学術・研究機関や外来手術センターを含むその他に区分される。
地域別インサイト
北米のエピジェネティクス医薬品および診断技術市場は、進行中の疾患の発生件数の増加、およびIllumina, Inc.（米国）、Gilead Sciences, Inc.（米国）、Celleron Therapeutics（米国）、LISEN lmprinting Diagnostics（米国）、Salarius Drugs, Inc.（米国）を含む主要かつダイナミックなプレイヤーの存在により、2022年に最大の市場シェアを占めました。
欧州のエピジェネティクス医薬品・診断技術市場は、遺伝性疾患の優位性の高まりと、遺伝性疾患を検出するためのエピジェネティクス検査の普及により、第2位の市場シェアを占めている。
アジア太平洋地域のエピジェネティクス医薬品・診断技術市場は、神経疾患の発症率の増加や、医薬品開発のための協調的な取り組みの拡大により、健全な市場成長を記録すると予測されています。2020年に明らかにされたアルツハイマー病の世界的な動向によると、中国、インド、南アジア、西太平洋近隣諸国を含む発展途上国では、老年人口の急速な増加により、アルツハイマー病の可能性が高くなっています。
主要企業
エピジェネティクス医薬品および診断技術の市場における主要企業は、Hologic, Inc.（米国）、Gilead Sciences, Inc.（米国）、Celleron Therapeutics（米国）、Illumina, Inc.（米国）、AstraZeneca PLC（英国）、LISEN lmprinting Diagnostics（米国）、Salarius Pharmaceuticals, Inc.（米国）、Jubilant Therapeutics（米国）、Oryzon Genomics（スペイン）、Epiaxis Therapeutics（オーストラリア）である。

ページTOPに戻る

TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. DEFINITION
2.2. SCOPE OF THE STUDY
2.2.1. RESEARCH OBJECTIVE
2.2.2. ASSUMPTIONS
2.2.3. LIMITATIONS
3. RESEARCH METHODOLOGY
3.1. OVERVIEW
3.2. DATA MINING
3.3. SECONDARY RESEARCH
3.4. PRIMARY RESEARCH
3.4.1. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2. BREAKDOWN OF PRIMARY RESPONDENTS
3.5. FORECASTING TECHNIQUE
3.6. MARKET SIZE ESTIMATION
3.6.1. BOTTOM-UP APPROACH
3.6.2. TOP-DOWN APPROACH
3.7. DATA TRIANGULATION
3.8. VALIDATION
4. MARKET DYNAMICS
4.1. OVERVIEW
4.2. DRIVERS
4.3. RESTRAINTS
4.4. OPPORTUNITIES
5. MARKET FACTOR ANALYSIS
5.1. VALUE CHAIN ANALYSIS
5.2. PORTER’S FIVE FORCES ANALYSIS
5.2.1. BARGAINING POWER OF SUPPLIERS
5.2.2. BARGAINING POWER OF BUYERS
5.2.3. THREAT OF NEW ENTRANTS
5.2.4. THREAT OF SUBSTITUTES
5.2.5. INTENSITY OF RIVALRY
5.3. COVID-19 IMPACT ANALYSIS
5.3.1. MARKET IMPACT ANALYSIS
5.3.2. REGIONAL IMPACT
5.3.3. OPPORTUNITY AND THREAT ANALYSIS
6. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE
6.1. OVERVIEW
6.2. DNA METHYLTRANSFERASES (DNMTS) INHIBITORS
6.2.1. AZACITIDINE
6.2.2. DECITABINE
6.2.3. OTHERS
6.3. HISTONE DEACETYLASES (HDACS) INHIBITORS
6.3.1. VORINOSTAT
6.3.2. ROMIDEPSIN
6.3.3. OTHERS
6.4. HISTONE METHYLTRANSFERASE (HMT) INHIBITORS
6.5. OTHERS
7. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES
7.1. OVERVIEW
7.2. DNA METHYLATION
7.3. HISTONE MODIFICATION ANALYSIS
7.4. OTHERS
8. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION
8.1. OVERVIEW
8.2. ONCOLOGY
8.3. NEUROLOGY
8.4. AUTOIMMUNE DISEASES
8.5. OTHERS
9. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER
9.1. OVERVIEW
9.2. HOSPITALS & CLINICS
9.3. DIAGNOSTIC LABORATORIES
9.4. OTHERS
10. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY REGION
10.1. OVERVIEW
10.1. NORTH AMERICA
10.1.1. US
10.1.2. CANADA
10.2. EUROPE
10.2.1. GERMANY
10.2.2. FRANCE
10.2.3. UK
10.2.4. ITALY
10.2.5. SPAIN
10.2.6. REST OF EUROPE
10.3. ASIA-PACIFIC
10.3.1. CHINA
10.3.2. INDIA
10.3.3. JAPAN
10.3.4. SOUTH KOREA
10.3.5. AUSTRALIA
10.3.6. REST OF ASIA-PACIFIC
10.4. REST OF THE WORLD
10.4.1. MIDDLE EAST
10.4.2. AFRICA
10.4.3. LATIN AMERICA
11. COMPANY LANDSCAPE
11.1. OVERVIEW
11.2. COMPETITIVE ANALYSIS
11.3. MARKET SHARE ANALYSIS
11.4. MAJOR GROWTH STRATEGY IN THE GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET
11.5. COMPETITIVE BENCHMARKING
11.6. LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET
11.7. KEY DEVELOPMENTS AND GROWTH STRATEGIES
11.7.1. NEW PRODUCT LAUNCH
11.7.2. MERGER & ACQUISITIONS
11.7.3. JOINT VENTURES
11.8. MAJOR PLAYERS FINANCIAL MATRIX
11.8.1. SALES & OPERATING INCOME, 2022
11.8.2. MAJOR PLAYERS R&D EXPENDITURE. 2022
12. COMPANY PROFILES
12.1. HOLOGIC, INC.
12.1.1. COMPANY OVERVIEW
12.1.2. FINANCIAL OVERVIEW
12.1.3. PRODUCTS OFFERED
12.1.4. KEY DEVELOPMENTS
12.1.5. SWOT ANALYSIS
12.1.6. KEY STRATEGIES
12.2. GILEAD SCIENCES, INC.
12.2.1. COMPANY OVERVIEW
12.2.2. FINANCIAL OVERVIEW
12.2.3. PRODUCTS OFFERED
12.2.4. KEY DEVELOPMENTS
12.2.5. SWOT ANALYSIS
12.2.6. KEY STRATEGIES
12.3. CELLERON THERAPEUTICS
12.3.1. COMPANY OVERVIEW
12.3.2. FINANCIAL OVERVIEW
12.3.3. PRODUCTS OFFERED
12.3.4. KEY DEVELOPMENTS
12.3.5. SWOT ANALYSIS
12.3.6. KEY STRATEGIES
12.4. ILLUMINA, INC.
12.4.1. COMPANY OVERVIEW
12.4.2. FINANCIAL OVERVIEW
12.4.3. PRODUCTS OFFERED
12.4.4. KEY DEVELOPMENTS
12.4.5. SWOT ANALYSIS
12.4.6. KEY STRATEGIES
12.5. ASTRAZENECA PLC
12.5.1. COMPANY OVERVIEW
12.5.2. FINANCIAL OVERVIEW
12.5.3. PRODUCTS OFFERED
12.5.4. KEY DEVELOPMENTS
12.5.5. SWOT ANALYSIS
12.5.6. KEY STRATEGIES
12.6. LISEN LMPRINTING DIAGNOSTICS
12.6.1. COMPANY OVERVIEW
12.6.2. FINANCIAL OVERVIEW
12.6.3. PRODUCTS OFFERED
12.6.4. KEY DEVELOPMENTS
12.6.5. SWOT ANALYSIS
12.6.6. KEY STRATEGIES
12.7. SALARIUS PHARMACEUTICALS, INC.
12.7.1. COMPANY OVERVIEW
12.7.2. FINANCIAL OVERVIEW
12.7.3. PRODUCTS OFFERED
12.7.4. KEY DEVELOPMENTS
12.7.5. SWOT ANALYSIS
12.7.6. KEY STRATEGIES
12.8. JUBILANT THERAPEUTICS
12.8.1. COMPANY OVERVIEW
12.8.2. FINANCIAL OVERVIEW
12.8.3. PRODUCTS OFFERED
12.8.4. KEY DEVELOPMENTS
12.8.5. SWOT ANALYSIS
12.8.6. KEY STRATEGIES
12.9. ORYZON GENOMICS
12.9.1. COMPANY OVERVIEW
12.9.2. FINANCIAL OVERVIEW
12.9.3. PRODUCTS OFFERED
12.9.4. KEY DEVELOPMENTS
12.9.5. SWOT ANALYSIS
12.9.6. KEY STRATEGIES
12.10. EPIAXIS THERAPEUTICS
12.10.1. COMPANY OVERVIEW
12.10.2. FINANCIAL OVERVIEW
12.10.3. PRODUCTS OFFERED
12.10.4. KEY DEVELOPMENTS
12.10.5. SWOT ANALYSIS
12.10.6. KEY STRATEGIES
13. APPENDIX
13.1. REFERENCES
13.2. RELATED REPORTS

ページTOPに戻る

図表リスト

LIST OF TABLES

TABLE 1 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, SYNOPSIS, 2019–2032

TABLE 2 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, ESTIMATES & FORECAST, 2019–2032 (USD BILLION)

TABLE 3 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 4 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 5 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 6 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 7 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 8 GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 9 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 10 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 11 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 12 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 13 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 14 NORTH AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 15 US: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 16 US: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 17 US: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 18 US: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 19 US: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 20 US: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 21 CANADA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 22 CANADA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 23 CANADA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 24 CANADA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 25 CANADA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 26 CANADA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 1 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 2 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 3 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 4 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 5 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 6 EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 7 GERMANY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 8 GERMANY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 9 GERMANY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 10 GERMANY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 11 GERMANY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 12 GERMANY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 13 FRANCE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 14 FRANCE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 15 FRANCE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 16 FRANCE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 17 FRANCE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 18 FRANCE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 19 ITALY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 20 ITALY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 21 ITALY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 22 ITALY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 23 ITALY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 24 ITALY: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 25 SPAIN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 26 SPAIN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 27 SPAIN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 28 SPAIN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 29 SPAIN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 30 SPAIN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 31 UK: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 32 UK: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 33 UK: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 34 UK: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 35 UK: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 36 UK: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 37 REST OF EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 38 REST OF EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 39 REST OF EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 40 REST OF EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 41 REST OF EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 42 REST OF EUROPE: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 43 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 44 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 45 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 46 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 47 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 48 ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 49 JAPAN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 50 JAPAN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 51 JAPAN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 52 JAPAN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 53 JAPAN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 54 JAPAN: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 55 CHINA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 56 CHINA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 57 CHINA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 58 CHINA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 59 CHINA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 60 CHINA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 61 INDIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 62 INDIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 63 INDIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 64 INDIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 65 INDIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 66 INDIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 67 AUSTRALIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 68 AUSTRALIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 69 AUSTRALIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 70 AUSTRALIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 71 AUSTRALIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 72 AUSTRALIA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 73 SOUTH KOREA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 74 SOUTH KOREA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 75 SOUTH KOREA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 76 SOUTH KOREA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 77 SOUTH KOREA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 78 SOUTH KOREA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 79 REST OF ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 80 REST OF ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 81 REST OF ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 82 REST OF ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 83 REST OF ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 84 REST OF ASIA-PACIFIC: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 85 REST OF THE WORLD: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 86 REST OF THE WORLD: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 87 REST OF THE WORLD: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 88 REST OF THE WORLD: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 89 REST OF THE WORLD: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 90 REST OF THE WORLD: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 91 MIDDLE EAST: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 92 MIDDLE EAST: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 93 MIDDLE EAST: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 94 MIDDLE EAST: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 95 MIDDLE EAST: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 96 MIDDLE EAST: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 97 AFRICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 98 AFRICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 99 AFRICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 100 AFRICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 101 AFRICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 102 AFRICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 103 LATIN AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE, 2019–2032 (USD BILLION)

TABLE 104 LATIN AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DNA METHYLTRANSFERASES (DNMTS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 105 LATIN AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY HISTONE DEACETYLASES (HDACS) INHIBITORS, BY TYPE, 2019–2032 (USD BILLION)

TABLE 106 LATIN AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES, 2019–2032 (USD BILLION)

TABLE 107 LATIN AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 108 LATIN AMERICA: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER, 2019–2032 (USD BILLION)

ページTOPに戻る

Table of Contents
List of Tables/Graphs

Summary

Epigenetics Drugs and Diagnostic Technologies Market Research Report Forecast to 2032

Market Overview
The Epigenetics Drugs and Diagnostic Technologies Market is anticipated to register a substantial CAGR of 21.90% during the review period.
The development of the market is driven by elements like the rising pervasiveness of persistent diseases like Focal Sensory system (CNS) diseases and oncology and the rising number of product dispatches and pipeline products.
The rising incidences of ongoing diseases of the focal sensory system across the globe are expanding the demand for epigenetic drugs and diagnostic technologies. Epigenetics significantly treat focal sensory system diseases, including Alzheimer's, Huntington's disease, schizophrenia, chemical imbalance, and bipolar disorder. Moreover, these drugs have low poisonousness and can be given in mix with different kinds of drugs for better treatment.
Additionally, epigenetics has shown extraordinary outcomes in treating malignant growth, and these drugs could switch off Deoxyribonucleic Acid (DNA). According to GLOBOCAN 2020, bosom disease accounted for the biggest offer, followed by lung, colorectum, prostate, stomach, and different malignant growths.
Market Segmentation
The market segments of epigenetics drugs and diagnostic technologies, based on drug type, into DNA methyltransferases (DNMTs) inhibitors, histone deacetylases (HDACs) inhibitors, histone methyltransferase (HMT) inhibitors, and others including bromodomain inhibitors, protein methyltransferase inhibitors, and histone acetyltransferases (HAT) inhibitors. The DNA methyltransferases (DNMTs) inhibitors segment is further segmented into azacitidine, decitabine, and others including zebularine, hydralazine, and procaine, and histone deacetylases (HDACs) inhibitors are further segmented into vorinostat, romidepsin, and others including belinostat, panobinostat, and trichostatin A.
The diagnostic technologies segment is classified into DNA methylation and histone modification analysis and others, including non-coding RNA analysis and epigenomic profiling.
Based on application, the market is separated into oncology, neurology, autoimmune diseases, and others. Based on end users the market is segmented into hospitals & and clinics, diagnostic centers, and others, including academic and research institutes and ambulatory surgical centers.
Regional Insights
North America epigenetics drugs and diagnostic technologies market held the biggest market share in 2022, due to the rising incidences of ongoing diseases and the presence of major and dynamic players including Illumina, Inc. (US), Gilead Sciences, Inc. (US), Celleron Therapeutics (US), LISEN lmprinting Diagnostics (US), and Salarius Drugs, Inc. (US).
Europe's epigenetics drugs and diagnostic technologies market accounted for the second-biggest market share due to the rising predominance of hereditary disorders and the send-off of epigenetic tests to detect hereditary disorders.
The Asia-Pacific epigenetics drugs and diagnostic technologies market is anticipated to register a healthy market growth owing to the developing incidence of neurological diseases and expanding coordinated efforts for the development of the drugs. According to the Alzheimer's Disease Global revealed in 2020, there are higher possibilities of Alzheimer's in developing nations including China, India, South Asia, and Western Pacific neighbors due to the quick development of the geriatric populace.
Major Players
Key Companies in the market of Epigenetics Drugs and Diagnostic Technologies are Hologic, Inc. (US), Gilead Sciences, Inc. (US), Celleron Therapeutics (US), Illumina, Inc. (US), AstraZeneca PLC (UK), LISEN lmprinting Diagnostics (US), Salarius Pharmaceuticals, Inc. (US), Jubilant Therapeutics (US), Oryzon Genomics (Spain), and Epiaxis Therapeutics (Australia).

ページTOPに戻る

List of Tables/Graphs

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

Market Research Future 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Market Research Future社はどのような調査会社ですか?

マーケットリサーチフューチャー（Market Research Future）は世界市場を幅広く調査し、主要分野、地域、国レベルの調査レポートを出版しています。下記分野については、分野毎に専... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

エピジェネティクス医薬品と診断技術の市場調査レポート：2032年までの予測

サマリー

目次

図表リスト

Summary

Table of Contents

List of Tables/Graphs

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

Market Research Future 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

Market Research Future社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?